<DOC>
	<DOC>NCT00092742</DOC>
	<brief_summary>The purpose of this study is to evaluate the long-term safety of an investigational drug versus an approved drug for the relief of pain in patients with rheumatoid arthritis.</brief_summary>
	<brief_title>Investigational Drug Versus an Approved Drug in Patients With Rheumatoid Arthritis (0663-072)</brief_title>
	<detailed_description>The duration of treatment is 12 months.</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<mesh_term>Etoricoxib</mesh_term>
	<criteria>Males and females 50 years or older with rheumatoid arthritis. History of gastrointestinal malabsorption or inflammatory bowel disease History of heart problems such as: congestive heart failure (CHF), heart attack or high blood pressure.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Arcoxia</keyword>
</DOC>